Shares of Hikma Pharmaceuticals PLC (LON:HIK – Get a rating) received a consensus recommendation of “Hold” from the seven rating agencies that cover the company, reports Marketbeat.com. Six equity research analysts rated the stock with a hold recommendation and one issued a buy recommendation on the company. The average 1-year price target among brokers who have issued ratings on the stock in the past year is 2,125 GBX ($25.68).
Several stock analysts have recently released reports on HIK shares. JPMorgan Chase & Co. cut its price target on Hikma Pharmaceuticals from 1,900 GBX ($22.96) to 1,760 GBX ($21.27) and set a “neutral” rating on the stock in a memo. research from Thursday, August 11. Berenberg Bank reaffirmed a “hold” rating and set a price target of 1,440 GBX ($17.40) on shares of Hikma Pharmaceuticals in a research report on Tuesday. Finally, Barclays reaffirmed an “equal weight” rating and set a target price of 1,750 GBX ($21.15) on shares of Hikma Pharmaceuticals in a report on Friday, September 30.
Hikma Pharmaceuticals is trading down 0.6%
Shares of HIK opened at 1,293.50 GBX ($15.63) on Thursday. Hikma Pharmaceuticals has a 52-week minimum of 1,176.50 GBX ($14.22) and a 52-week maximum of 2,496 GBX ($30.16). The company’s fifty-day moving average is 1,402.72 GBX and its 200-day moving average is 1,657.01 GBX. The company has a debt ratio of 70.79, a quick ratio of 1.27 and a current ratio of 2.12. The company has a market capitalization of £2.85 billion and a price to earnings ratio of 966.04.
Hikma Pharmaceuticals cuts its dividend
The company also recently disclosed a dividend, which was paid on Monday, September 19. Shareholders of record on Thursday August 18 received a dividend of $0.19. This represents a dividend yield of 0.89%. The ex-dividend date was Thursday, August 18. Hikma Pharmaceuticals’ dividend payout ratio is 38.83%.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, markets and sells a range of generic, branded and licensed pharmaceutical products. The Company offers its products in solid, semi-solid, liquid and injectable final dosage forms. It operates through three segments: injectables, generics and branded.
Read more
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to contact@marketbeat.com.
Before you consider Hikma Pharmaceuticals, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Hikma Pharmaceuticals was not on the list.
While Hikma Pharmaceuticals currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here
